BLOOD SUGAR AND ALCOHOL

How Alcohol Disrupts Blood Glucose

Alcohol disrupts blood glucose regulation through several mechanisms running at once. Ethanol metabolism in the liver inhibits gluconeogenesis (the liver's production of new glucose from non-carbohydrate sources), which can lead to hypoglycemia in the hours after drinking, especially on an empty stomach. The redox shift from NADH accumulation during ethanol metabolism alters the kinetics of several blood-sugar-relevant enzymes. Chronic alcohol exposure also disrupts pancreatic beta-cell function and reduces peripheral insulin sensitivity through inflammatory pathways¹.

The combined effect is that drinking, even moderately, perturbs the systems that maintain blood glucose homeostasis -- both during and after the alcohol exposure window.

What DHM Does to Glucose Homeostasis

DHM has a documented effect on insulin sensitivity and glucose homeostasis in animal models of metabolic dysfunction. A 2019 study in db/db mice (a standard diabetes model) showed DHM improved insulin sensitivity through upregulation of insulin receptor substrate-1 (IRS-1) tyrosine phosphorylation, with measurable reductions in fasting blood glucose and insulin resistance markers². A 2021 study examining inflammation-induced insulin resistance demonstrated DHM activates the phospholipase C-CaMKK-AMPK signaling pathway, which is one of the primary regulatory pathways for cellular insulin sensitivity³.

A 2017 study in Zucker diabetic fatty rats reported that DHM administration delayed the onset of hyperglycemia by four weeks, preserved pancreatic beta-cell mass, and improved lipid profile measures more effectively than rosiglitazone (a standard diabetes medication) in the same comparison⁴. The insulin-sensitivity effect is documented across multiple animal diabetes models, in the published rodent data at least.

Why This Connects to the Alcohol Use Case

The mechanistic overlap matters. The AMPK signaling pathway that DHM activates for insulin sensitivity is the same pathway implicated in mitochondrial biogenesis and in restoring metabolic balance after the NAD+ depletion that ethanol metabolism produces. The downstream effects on glucose homeostasis come along with the hepatoprotective and metabolic-rebalancing effects that drive the formula's primary alcohol-recovery use case.

(this is the most carefully bounded claim H180 makes, because the underlying DHM diabetes literature is exclusively preclinical and the regulatory line for blood-sugar claims is unusually strict.)

Why the Claim Is Bounded to "In the Normal Range"

The "regulates blood sugar levels in the normal range" qualifier is doing important regulatory work. Diabetes treatment is a disease-treatment claim that no dietary supplement can make under DSHEA. The claim has to stay in the structure-function range, supporting normal blood sugar regulation in healthy individuals rather than treating diabetes or any other clinical glucose-regulation disorder.

The DHM diabetes-model literature is preclinical, with no human clinical trials of DHM specifically for diabetes outcomes. The bounded claim aligns the regulatory framing with the actual evidence base¹.

What This Page Is Not Claiming

The blood-sugar claim is bounded ot maintaining values already in the normal range adn we do not extrapolate the animal-diabetes data into human treatment claims. We are not claiming H180 treats diabetes, prevents diabetes, lowers HbA1c, or substitutes for any clinical management of glucose dysregulation. Anyone with diabetes or pre-diabetic blood glucose values should be working with a clinician.

For the related mitochondrial-signaling pathway that connects DHM's metabolic effects, see Mitochondrial Biogenesis. For the headline alcohol-metabolism mechanism, see Aldehyde Metabolism Explained.